drugset / Trial / NCT00078572

Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer

NCT00078572

Phase 3 Completed 408 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelTreatment

Summary

This study was designed to compare the efficacy and safety of an oral dual tyrosine kinase inhibitor in combination with capecitabine versus capecitabine alone in women with locally advanced or metastatic breast cancer that has not responded to previous therapy.

Timeline

Start
2004-03
Primary completion
2006-04
Completion
2010-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 2000 mg/m2 Oral
Subject Capecitabine Small molecule 2500 mg/m2 Oral
Subject Lapatinib Small molecule 1250 mg Oral

Indications